HCV NS5A作为抗病毒治疗靶点:从验证到Ombitasvir和Pibrentasvir作为节省ifn的HCV治疗成分的发现和发展

{"title":"HCV NS5A作为抗病毒治疗靶点:从验证到Ombitasvir和Pibrentasvir作为节省ifn的HCV治疗成分的发现和发展","authors":"R. Wagner, D. DeGoey, J. Randolph, C. KruegerAllan, M. Matulenko, W. Kati","doi":"10.1007/7355_2018_50","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":23098,"journal":{"name":"Topics in Medicinal Chemistry","volume":"112 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments\",\"authors\":\"R. Wagner, D. DeGoey, J. Randolph, C. KruegerAllan, M. Matulenko, W. Kati\",\"doi\":\"10.1007/7355_2018_50\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":23098,\"journal\":{\"name\":\"Topics in Medicinal Chemistry\",\"volume\":\"112 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Topics in Medicinal Chemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/7355_2018_50\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/7355_2018_50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}